Spinal Manipulation May Reduce Lumbar Spine Reoperations
24 Jan 2024
Clinical ResultClinical Study
WEDNESDAY, Jan. 24, 2024 -- Spinal manipulative therapy (SMT) may cut lumbar spine reoperation in adults experiencing lumbosacral radiculopathy (LSR) at least one year after lumbar discectomy, according to a study published online Jan. 10 in BMC Musculoskeletal Disorders.
Robert J. Trager, D.C., from Case Western Reserve University in Cleveland, and colleagues compared rates of lumbar spine reoperation for adult patients with LSR following lumbar discectomy undergoing chiropractic SMT versus those receiving usual care without chiropractic SMT. The analysis included 378 patients in each group.
The researchers found that lumbar spine reoperation was less frequent in the SMT cohort compared with the usual care cohort (SMT: 7 percent; usual care: 13 percent), yielding a risk ratio of 0.55. Among the SMT group, nearly three-quarters of participants (72 percent) had one or more follow-up SMT visit (median, six visits).
"While these findings hold promise for clinical implications, they should be corroborated by a prospective study including measures of pain, disability, and safety to confirm their relevance," the authors write. "We cannot exclude the possibility that our results stem from a generalized effect of engaging with a non-surgical clinician, a factor that may extend to related contexts such as physical therapy or acupuncture."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.